AngioDynamics, Inc. (NASDAQ:ANGO) stock fell 5.43% (As on April 3, 12:20:58 AM UTC-4, Source: Google Finance) after the company reported upbeat third-quarter earnings along with an improved full-year guidance. the company is “well positioned” to deliver profitable growth going forward, thanks to its portfolio strengthened by recent catalysts, including the Food and Drug Administration (FDA) clearance for its NanoKnife System for prostate tissue ablation. The company is seeing impressive momentum across the MedTech franchise, which grew over 20% for the second quarter in a row, driven by growth within each of the MedTech platform technologies, Auryon, AngioVac, AlphaVac, and NanoKnife. At February 28, 2025, the Company had $44.8 million in cash and cash equivalents compared to $54.1 million in cash and cash equivalents at November 30, 2024.

Moreover, Med Tech net sales were $31.3 million, a 22.2% increase from $25.7 million in the prior-year period, driven by strength across all product lines, including Auryon sales of $13.9 million, which increased 17.3%, AngioVac sales of $6.8 million, which increased 23.1%, AlphaVac sales of $3.0 million, which increased 161.4%, and NanoKnife disposable sales of $4.9 million, which increased 16.2%. Total NanoKnife sales, including capital, of $6.3 million, increased 5.3%. Med Device net sales were $40.7 million, an increase of 0.9% compared to $40.3 million in the prior-year period. U.S. net sales in the third quarter of fiscal 2025 were $61.3 million, an increase of 9.9% from $55.8 million a year ago. International net sales were $10.7 million, an increase of 5.1%, compared to $10.1 million a year ago.

ANGO in the third quarter of FY25 has reported the adjusted earnings per share of 3 cents, beating the analysts’ estimates for the adjusted loss per share of 13 cents, according to Zacks Consensus Estimate. The company had reported the adjusted revenue growth of 9.2 percent to $72 million in the third quarter of FY25, beating the analysts’ estimates for revenue by 2%.

The medical technology company now expects net sales to be in the range of $285 to $288 million for the fiscal year 2025, up from previously issued guidance of $282 to $288 million, owing to increased medical technology net sales. The company expects adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) for the year to be $4 to $5 million, an increase from prior guidance of $1 to $3 million. It expects adjusted loss per share in the range of $0.31 to $0.34, an improvement from prior guidance of a loss of $0.34 to $0.38.